IRIS UniCatt

Richeldi, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.741
AS - Asia 8.303
EU - Europa 6.231
SA - Sud America 1.984
AF - Africa 285
OC - Oceania 65
Continente sconosciuto - Info sul continente non disponibili 10
Totale 26.619
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.316
SG - Singapore 3.653
IT - Italia 1.788
BR - Brasile 1.624
CN - Cina 1.591
SE - Svezia 1.013
VN - Vietnam 888
DE - Germania 586
FR - Francia 575
PL - Polonia 461
GB - Regno Unito 399
BD - Bangladesh 357
IE - Irlanda 334
JP - Giappone 275
ID - Indonesia 274
HK - Hong Kong 271
FI - Finlandia 266
IN - India 256
CA - Canada 227
RU - Federazione Russa 203
MX - Messico 125
AR - Argentina 124
KR - Corea 101
NL - Olanda 100
AT - Austria 96
IQ - Iraq 88
TR - Turchia 88
ZA - Sudafrica 66
ES - Italia 62
UA - Ucraina 62
BE - Belgio 59
SA - Arabia Saudita 58
PK - Pakistan 57
AU - Australia 51
CO - Colombia 50
EC - Ecuador 46
IR - Iran 45
MA - Marocco 41
CH - Svizzera 39
VE - Venezuela 38
CZ - Repubblica Ceca 35
JO - Giordania 32
EG - Egitto 31
PY - Paraguay 30
AE - Emirati Arabi Uniti 28
PH - Filippine 28
TN - Tunisia 28
TW - Taiwan 28
CI - Costa d'Avorio 27
LT - Lituania 26
PE - Perù 26
UZ - Uzbekistan 26
MY - Malesia 22
KE - Kenya 20
IL - Israele 19
UY - Uruguay 19
DZ - Algeria 17
RO - Romania 16
CL - Cile 15
PT - Portogallo 15
AZ - Azerbaigian 14
NZ - Nuova Zelanda 14
KZ - Kazakistan 13
CR - Costa Rica 12
ET - Etiopia 12
GR - Grecia 12
NP - Nepal 12
BO - Bolivia 11
JM - Giamaica 11
TH - Thailandia 11
NO - Norvegia 9
AL - Albania 8
AO - Angola 8
BG - Bulgaria 8
EU - Europa 8
OM - Oman 8
SN - Senegal 8
TT - Trinidad e Tobago 8
DK - Danimarca 7
HR - Croazia 7
KG - Kirghizistan 7
LB - Libano 7
MD - Moldavia 7
PA - Panama 7
HN - Honduras 6
LK - Sri Lanka 6
LV - Lettonia 6
NG - Nigeria 6
BY - Bielorussia 5
BZ - Belize 5
DO - Repubblica Dominicana 5
EE - Estonia 5
GA - Gabon 5
GE - Georgia 5
HU - Ungheria 5
NI - Nicaragua 5
PR - Porto Rico 5
PS - Palestinian Territory 5
SD - Sudan 5
SK - Slovacchia (Repubblica Slovacca) 5
Totale 26.554
Salva come PNG Salva come JPEG
Città #
Singapore 1.921
San Jose 1.093
Ashburn 1.061
Chandler 676
Warsaw 433
Beijing 411
Rome 381
Fairfield 333
Dublin 331
New York 316
Milan 304
Ho Chi Minh City 295
Los Angeles 262
Tokyo 238
Hong Kong 236
Jakarta 227
Lauterbourg 217
Hefei 206
The Dalles 200
Wilmington 193
Hanoi 192
Dallas 189
Helsinki 185
Houston 169
Chicago 161
Munich 158
Boston 157
Woodbridge 157
Seattle 151
Princeton 148
São Paulo 147
Frankfurt am Main 138
San Mateo 136
Council Bluffs 128
St Louis 121
Moscow 116
Ann Arbor 106
Cambridge 95
Nuremberg 92
Boardman 91
Buffalo 88
Santa Clara 85
London 75
Seoul 65
Kent 64
North Bergen 62
Atlanta 59
Orem 58
Rio de Janeiro 58
Toronto 57
Tukwila 51
Brussels 49
Brooklyn 48
Paris 48
Mexico City 46
Jacksonville 45
Da Nang 43
Marseille 43
Montreal 43
Denver 41
Lappeenranta 41
Vienna 41
Bremen 37
Shanghai 37
Amsterdam 36
Stockholm 36
Augusta 34
Chennai 34
Phoenix 33
Amman 32
Johannesburg 32
Bologna 31
Nanjing 31
Washington 31
Baghdad 30
Dhaka 30
Düsseldorf 30
Poplar 30
Belo Horizonte 29
Dearborn 28
Hyderabad 28
Mumbai 28
Redwood City 28
San Francisco 28
Turku 28
Abidjan 27
Dong Ket 27
Hải Dương 27
Haiphong 26
Kish 25
Naples 25
Pune 25
Curitiba 24
Manchester 24
Cattolica 23
Dammam 23
Hangzhou 23
Tashkent 23
Ankara 22
Fortaleza 22
Totale 14.468
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 527
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. 441
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 327
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry 314
Idiopathic Pulmonary Fibrosis: State of the Art for 2023 240
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 238
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 235
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 231
Subclinical interstitial lung abnormalities: Lumping and splitting revisited 216
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 216
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 214
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis 209
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial 206
Vaccines and Myocardial Injury in Patients Hospitalized for COVID-19 Infection: the CardioCOVID-Gemelli Study 205
Malnutrition in COVID-19 survivors: prevalence and risk factors 203
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 202
A real-time integrated framework to support clinical decision making for covid-19 patients 200
Assessment of neurological manifestations in hospitalized patients with COVID-19 198
Residual respiratory impairment after COVID-19 pneumonia 196
COVID-19 atypical Parsonage-Turner syndrome: a case report 195
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 193
Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey 192
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 191
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials 191
Malnutrition in COVID-19 survivors: prevalence and risk factors 182
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue 180
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 179
Residual respiratory impairment after COVID-19 pneumonia 177
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis 171
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 170
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 169
Reply to Moodley and to Ravaglia et al 168
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 165
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 164
Sarilumab use in severe SARS-CoV-2 pneumonia 164
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 159
The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey 158
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials 154
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis 152
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment 151
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 149
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia 149
Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series 148
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 148
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society 146
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 145
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis 144
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study 142
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 141
Case of a 33-Year-Old Woman With Hemoptysis and Migrant Nodular Cavitary Lesions 139
Effect of Admilparant, an LPA1 Antagonist, on Disease Progression in Pulmonary Fibrosis 139
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 135
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 134
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 134
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 134
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: Preliminary results 132
Severe asthma: One disease and multiple definitions 131
Promising advances in treatments for the management of idiopathic pulmonary fibrosis 130
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study 129
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 128
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 128
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings 128
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 125
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations 124
Idiopathic pulmonary fibrosis 122
Antibody-based therapies for idiopathic pulmonary fibrosis 122
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 122
A randomized trial of pamrevlumab in patients with COVID-19 pneumonia 120
Nerandomilast in Patients with Progressive Pulmonary Fibrosis 120
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 120
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 119
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) 119
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper 119
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 118
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS®trials 117
Antibody-based therapies for idiopathic pulmonary fibrosis 117
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants 116
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 116
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression 115
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years 115
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer 115
Reliability of crackles in fibrotic interstitial lung disease: a prospective, longitudinal study 115
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 113
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 111
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 111
Novel insights in fibrotic pulmonary sarcoidosis 110
Current and Future Idiopathic Pulmonary Fibrosis Therapy 110
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions 110
Statin therapy and lung disorders 109
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 109
Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative 108
Reticulation is a Risk Factor of Progressive Subpleural non-Fibrotic Interstitial Lung Abnormalities 108
Advances with pharmacotherapy for the treatment of interstitial lung disease 108
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study 107
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial 107
COVID-19 and interstitial lung disease: Keep them separate 107
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis 106
Determinants and Evolution of Obstructive Sleep Apnea Syndrome After Myocardial Infarction 106
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement 106
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis 106
Totale 15.804
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.601
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.506 141 75 29 155 56 48 30 237 61 68 339 267
2022/20232.924 315 302 274 430 270 355 136 179 310 147 132 74
2023/20242.037 69 436 91 100 102 211 136 75 90 149 234 344
2024/20254.633 121 97 362 202 306 208 220 229 751 411 923 803
2025/202613.644 1.672 551 971 1.706 2.025 630 1.974 695 937 922 672 889
2026/202779 79 0 0 0 0 0 0 0 0 0 0 0
Totale 27.069